RxDoctor Payments Data

Stephen Kwan, MD

Cardiovascular Disease · Los Angeles, CANPI 1710082805

Payments from drug & device makers

$1,301in general payments, 2019–2025

Across 49 payments — averaging $26.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$658
  • Pfizer$141
  • Gilead$127
  • Amarin Pharma, Inc.$108
  • E.r. Squibb & Sons, L.L.C.$70
  • Boehringer Ingelheim$55
  • plus $142 from 4 others

What the payments were for

  • Food & beverage$1,23295%
  • Education$695%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,301 in reported general payments places this provider in the 40th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$118,926
Medicare patients
258
Services billed
1,515

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol121$118,712
EliquisApixaban89$118,110
KerendiaFinerenone47$57,645
LinzessLinaclotide45$54,166
VascepaIcosapent Ethyl124$48,930
Repatha SureclickEvolocumab69$46,866
BrilintaTicagrelor71$45,093
Ranolazine ErRanolazine387$35,980
JardianceEmpagliflozin38$34,020
DapagliflozinDapagliflozin Propanediol17$12,983
LokelmaSodium Zirconium Cyclosilicate13$10,420
Dexlansoprazole DrDexlansoprazole16$5,371
Combivent RespimatIpratropium/Albuterol Sulfate11$5,185
AliskirenAliskiren Hemifumarate12$4,044
Diltiazem 24hr Er (Cd)Diltiazem Hcl163$3,922

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta, Lokelma$658$174,225205 claims
PfizerEliquis$141$118,11089 claims
BayerKerendia$36$57,64547 claims
Boehringer IngelheimJardiance, Combivent Respimat$55$39,20549 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →